To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Structure-based ligand de… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Structure-based ligand design to overcome CYP inhibition in drug discovery projects

Review article
Authors Gisela Brändén
T. Sjogren
V. Schnecke
Y. F. Xue
Published in Drug Discovery Today
Volume 19
Issue 7
Pages 905-911
ISSN 1359-6446
Publication year 2014
Published at Department of Chemistry and Molecular Biology
Pages 905-911
Language en
Links dx.doi.org/10.1016/j.drudis.2014.03...
Keywords HUMAN CYTOCHROME P4502C9, METABOLISM PREDICTIONS, FUNCTIONAL RELEVANCE, RITONAVIR ANALOGS, 3A4, BINDING, INSIGHTS, DOCKING, 2D6, P4503A4, Pharmacology & Pharmacy, ATES OF AMERICA, V107, P18422
Subject categories Pharmacology

Abstract

Cytochrome P450 (CYP) enzymes are key players in xenobiotic metabolism, and inhibition of CYPs can therefore result in unwanted drug-drug interactions. Within drug discovery, CYP inhibition can cause delays in the progression of candidate drugs, or even premature closure of projects. During the past decade, a massive effort in the pharmaceutical industry and academic research has produced a wealth of structural information in the CYP field. In this short review, we will describe how structure-based approaches can be used in the pharmaceutical industry to work away from CYP inhibition, with a focus on the opportunities and challenges. We will show two examples from our own work where structural information on CYP2C9 and CYP3A4 inhibitor complexes have been successfully exploited in ongoing drug discovery projects.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?